JP Morgan Chase
RCEL icon

JP Morgan Chase’s Avita Medical RCEL Stock Holding History

JP Morgan Chase’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.49K Sell
2,232
-3,683
-62% -$15.9K ﹤0.01% 6932
2026
Q1 		$21.5K Buy
5,915
+830
+16% +$3.48K ﹤0.01% 6513
2025
Q4 		$17.5K Sell
5,085
-182
-3% -$726 ﹤0.01% 6539
2025
Q3 		$26.9K Sell
5,267
-7,789
-60% -$40.6K ﹤0.01% 6409
2025
Q2 		$69.1K Buy
13,056
+463
+4% +$3.37K ﹤0.01% 5772
2025
Q1 		$103K Sell
12,593
-40,113
-76% -$375K ﹤0.01% 5558
2024
Q4 		$675K Buy
52,706
+20,362
+63% +$240K ﹤0.01% 4889
2024
Q3 		$347K Buy
32,344
+8,985
+38% +$84.4K ﹤0.01% 5123
2024
Q2 		$185K Buy
23,359
+13,075
+127% +$124K ﹤0.01% 5199
2024
Q1 		$165K Sell
10,284
-6,344
-38% -$103K ﹤0.01% 5443
2023
Q4 		$228K Sell
16,628
-433
-3% -$4.96K ﹤0.01% 5318
2023
Q3 		$249K Sell
17,061
-2,431
-12% -$41.1K ﹤0.01% 4931
2023
Q2 		$332K Buy
19,492
+12,846
+193% +$188K ﹤0.01% 4749
2023
Q1 		$93K Buy
+6,646
New +$70.7K ﹤0.01% 5461
2022
Q2 		– Sell
-17,501
Closed -$149K – 6804
2022
Q1 		$149K Sell
17,501
-50,529
-74% -$466K ﹤0.01% 5328
2021
Q4 		$815K Buy
68,030
+17,902
+36% +$273K ﹤0.01% 4528
2021
Q3 		$889K Buy
50,128
+40,962
+447% +$773K ﹤0.01% 4404
2021
Q2 		$188K Buy
+9,166
New +$181K ﹤0.01% 5278
2020
Q3 		– Sell
-30,471
Closed -$931K – 5717
2020
Q2 		$931K Buy
30,471
+29,547
+3,198% +$904K ﹤0.01% 3561
2020
Q1 		$29K Buy
+924
New +$38.3K ﹤0.01% 4870

Other funds holding RCEL

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's RCEL Position: Q2 2026 in Review

JP Morgan Chase reduced its Avita Medical (RCEL) stake by 62% in Q2 2026, selling an estimated $15.9K and leaving 2,232 shares worth $9.49K. The position accounts for ﹤0.01% of the portfolio, ranked #6932.

JP Morgan Chase first reported a position in RCEL in Q1 2020 and has held it in 20 quarters since. The position peaked at $931K in Q2 2020. 73 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

  • JP Morgan Chase held 2,232 shares of Avita Medical worth $9.49K as of Q2 2026.
  • JP Morgan Chase sold 3,683 Avita Medical shares in Q2 2026, an estimated $15.9K.
  • Avita Medical made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6932 holding.
  • JP Morgan Chase first reported a position in Avita Medical in Q1 2020 and has held it in 20 quarters since.
  • JP Morgan Chase's Avita Medical position peaked at $931K in Q2 2020.
  • 73 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.